Led by Shivangi Sharma, with Pragya D. Yadav and Sarah Cherian as senior authors, the research team assembled a training dataset of 211 compounds drawn from three publicly curated sources: the Anti-Nipah database, the Nipah Virus Inhibitor Knowledgebase (NVIK), and PubChem, supplemented by a systematic review of the literature. This dataset contained both known inhibitors and inactive compounds, providing the labeled examples needed for supervised learning. Each molecule was converted into a numerical fingerprint using molecular descriptors calculated with the Mordred software, capturing features such as molecular weight, topological indices, electronic properties and atom-type electrotopological states. These descriptors serve as the language through which algorithms perceive chemical structure, allowing a model to learn which patterns of atoms, bonds and charge distributions correlate with antiviral activity against Nipah virus.

The investigators benchmarked seven different supervised machine learning algorithms: Support Vector Machines, Random Forest, Logistic Regression, Decision Tree, k-Nearest Neighbors, Artificial Neural Networks, and Ridge Classifier. Each was trained and evaluated using standard performance metrics, including accuracy, receiver operating characteristic analysis, and the Matthews correlation coefficient, a measure favored in cheminformatics because it remains robust even when classes are imbalanced. Among all seven, the Random Forest model, an ensemble method that aggregates the votes of hundreds of decision trees each trained on random subsets of the data, emerged as the clear winner. It achieved 95 percent accuracy on the training data and, critically, 86 percent on the held-out test set, indicating that the model had learned generalizable chemical patterns rather than simply memorizing its training examples. This balance between training and testing performance is the crucial test of any predictive model, and the Random Forest classifier passed it convincingly.

With a validated model in hand, the team unleashed it on a massive virtual haystack. The screening library comprised 9,021 compounds spanning FDA-approved drugs, molecules in preclinical development, investigational agents in clinical trials, and a dedicated collection of known antivirals. This breadth is the essence of drug repurposing: rather than spending a decade and billions of dollars synthesizing and testing novel chemicals, researchers can ask whether a molecule already optimized for safety, pharmacokinetics and manufacturability might also inhibit a new target. For a virus like Nipah, whose outbreaks are sporadic and unpredictable, the speed advantage is decisive. The machine learning classifier assigned each compound a probability of anti-Nipah activity, and the highest-scoring molecules advanced to the next stage of the pipeline.

That next stage was structural. The researchers focused on two of the virus’s most critical proteins: the attachment glycoprotein G, which sits on the viral surface and latches onto ephrin-B2 and ephrin-B3 receptors on human cells, initiating the entry process; and the RNA-dependent RNA polymerase (RdRp), the L-P protein complex that copies the viral genome and is essential for replication. Blocking either target can cripple the virus, and recent cryo-electron microscopy structures of the Nipah polymerase complex have finally given computational scientists an accurate map to work from. Using the Glide docking engine and the OPLS4 force field, the team computed binding poses and affinity scores for the shortlisted candidates within the binding pockets of both proteins, after careful preparation of protonation states and protein geometry.

Docking scores alone can be misleading, so the researchers added a second layer of physical rigor: molecular dynamics simulations. These simulations, run on the NAKSHATRA high-performance computing facility developed under India’s PM-Ayushman Bharat Health Infrastructure Mission, allow the protein-ligand complexes to flex and move in a simulated aqueous environment over time. A compound that binds well in a static docked pose but falls out of the binding pocket during dynamic simulation is unlikely to be a real inhibitor. By monitoring structural stability, root-mean-square deviations and persistent intermolecular contacts, the team separated genuine binders from computational artifacts.

The final verdict yielded eight candidate molecules, distributed across the two targets. Against the glycoprotein, three compounds stood out: 2,3,4,5,6-pentagalloylglucose (PGG), echinacoside, and parishin A. Against the RNA-dependent RNA polymerase, five compounds showed stable, high-affinity binding: neohesperidin dihydrochalcone, naringin dihydrochalcone, diosmin, orientin, and amikacin. Several of these names will be familiar to natural products chemists. PGG, a heavily galloylated tannin found in oak bark and various medicinal plants, has previously been shown to block influenza A virus and to inhibit the interaction between the SARS-CoV-2 spike protein and the human ACE2 receptor. Echinacoside, derived from Echinacea species, has documented antiviral activity against respiratory viruses and was recently flagged in computational studies against the Zika virus polymerase. Parishin A, a bioactive constituent of the orchid Gastrodia elata, has similarly been implicated in blocking viral entry in prior structural studies.

The polymerase-directed candidates are equally intriguing. Neohesperidin dihydrochalcone is, remarkably, a widely used artificial sweetener approved as a food additive in many countries, and it carries an extensive safety dossier along with documented anti-inflammatory and antioxidant properties; it has also been docked against SARS-CoV-2 proteins in earlier work. Diosmin, a flavonoid used as a vascular tonic in human medicine, has recently demonstrated antiviral potential against influenza A. Orientin, a luteolin glycoside found in passionflower and other botanicals, has been studied experimentally against the SARS-CoV-2 spike protein. Amikacin is the most surprising entry on the list: an aminoglycoside antibiotic in clinical use for decades, it belongs to a drug class that has been shown in independent research to enhance host resistance to viral infections through microbiota-independent mechanisms. Its strong binding to the Nipah polymerase adds a completely new dimension to its potential therapeutic profile.

The choice of targets reflects a deep understanding of Nipah virus biology. The G glycoprotein is the virus’s key to the cell, and its receptor-binding domain has been mapped at atomic resolution in multiple crystal structures, revealing precisely which residues engage ephrin-B2. Antibodies and small molecules that occlude this interface prevent attachment and fusion. The polymerase, meanwhile, is the engine of viral replication, and it has proven to be an Achilles’ heel for related paramyxoviruses: allosteric polymerase inhibitors developed against measles virus and respiratory syncytial virus suppress all RNA synthesis activity in those pathogens. A recent non-nucleotide allosteric inhibitor with pan-coronavirus activity has further demonstrated that polymerase targets can yield broad-spectrum antivirals, making the Nipah L-P complex a highly strategic point of attack. The availability of the cryo-EM structure of the Nipah L-P complex, published in late 2024, transformed this target from an aspirational goal into a practical docking substrate.

The current standard of care for Nipah infection remains rudimentary. Ribavirin, used empirically during the 1998-1999 Malaysian outbreak, showed only ambiguous benefit in observational studies of acute encephalitis patients. The monoclonal antibody m102.4, which neutralizes the G glycoprotein, has been administered on a compassionate basis but is not licensed. Remdesivir and favipiravir both protect animals in challenge experiments, and remdesivir has been tested in compassionate-use settings, yet neither is an approved Nipah therapy. Vaccine development is accelerating: a recombinant vesicular stomatitis virus vector vaccine has advanced toward human trials in outbreak regions, and the University of Oxford launched the world’s first Phase II Nipah vaccine trial with CEPI support. But vaccines alone cannot treat established infections, and the unpredictable geography of spillovers from fruit bats to humans through contaminated date palm sap or direct animal contact means that a stockpiled, orally available antiviral would be an invaluable component of outbreak preparedness.

The authors emphasize that their integrative approach, combining machine learning prediction with structure-based validation, is designed precisely to compress the timeline between an outbreak’s emergence and the availability of candidate therapeutics. Because every compound that survived the pipeline already exists in the pharmacopeia, at least in some form, downstream development could in principle bypass many early-stage hurdles of traditional drug discovery. The team also notes that all data used in the study are publicly available, and the models were built entirely from open resources, a transparency that should allow other groups to reproduce, refine and extend the approach.

Caveats remain, as they do for all purely computational studies. Docking and molecular dynamics predictions must ultimately be confirmed in live-virus assays, which require high-containment BSL-4 laboratories, and subsequently in animal models and human trials. Physicochemical liabilities, metabolic stability and oral bioavailability of the larger natural-product-derived molecules will need careful evaluation using tools such as SwissADME and ADMETlab, both of which the authors employed in their computational assessment. Nevertheless, the study stands as a template for how artificial intelligence can transform the response to neglected, high-consequence pathogens. By converting scattered inhibitor data into a predictive engine and then filtering thousands of real-world drugs through docking and dynamics, the Pune team has handed the Nipah research community a short, chemically diverse and mechanistically grounded list of candidates worth testing the moment the next outbreak appears. In a field where every month of delay can cost lives, that kind of head start could prove invaluable.

Hepatitis C virus represents a critical public health challenge, affecting millions of people globally. Traditional models often struggle to accommodate the intricate and dynamic nature of viral infections. The research by Sabir, Yessengaliyev, and Temirzhan introduces a cutting-edge radial basis function (RBF) neural network architecture that aims to improve predictions regarding HCV behavior. This model is not merely an attempt to refine existing methods but signifies a pivotal shift in how we approach viral modeling.

The first significant advantage of the RBF neural network lies in its ability to handle nonlinear relationships within data. Viruses like HCV exhibit rapid mutations, making them unpredictable and challenging to model accurately. By utilizing RBFs, which are well-suited for function approximation in high-dimensional spaces, the researchers have created a mechanism that can adapt to these fluctuations and yield more accurate predictions. This adaptability is crucial, especially given the viral genome’s propensity for rapid evolution.

In establishing the theoretical underpinnings of their research, the authors conducted extensive simulations that compared their RBF model’s performance against traditional linear and nonlinear models. The results were illuminating, revealing that the RBF neural structure significantly outperformed its predecessors. This performance leap is attributed to the model’s ability to interpolate complex data points and leverage local information more effectively than more conventional approaches.

Furthermore, the researchers applied their new model to real-world data sets related to HCV infection rates and treatment outcomes. The results indicate a striking correlation between their model’s predictions and observed infection dynamics. Such validation not only reinforces the model’s credibility but also its potential usefulness in public health epidemiology—providing a robust tool for policymakers and health officials.

The implications of this research extend beyond mere academic curiosity. As global health organizations strive to devise effective treatment plans, the incorporation of advanced computational models like the one presented by Sabir and colleagues could offer pivotal insights. Understanding the spread and mutation patterns of HCV can lead to more informed vaccinations, targeted therapies, and ultimately, better patient outcomes.

Moreover, this novel approach highlights the growing intersection of machine learning and virology. Researchers are increasingly recognizing that problems within biological systems can often be framed as computational challenges. The success of this RBF neural network model calls for a reevaluation of the tools we use in microbiology, hinting at a future where machine learning techniques are integral to all stages of viral research.

The findings from this research open the door to further exploration. Future studies could expand upon this model to tackle additional viral pathogens beyond HCV. By tweaking the RBF architecture and applying it to other viruses, researchers could uncover more about viral behavior, adaptive strategies, and the potential for cross-species transmissions. Each discovery could propel us closer to combating infectious diseases globally.

As we delve deeper into the era of artificial intelligence, it is essential to consider ethical implications that may arise from these advanced models. While the potential for improving health outcomes is vast, the accuracy and reliability of predictions must remain paramount. Ongoing evaluation and oversight will be crucial as we integrate such models into public health strategies and clinical applications.

The authors of this groundbreaking study are hopeful that their RBF neural network could also be adapted to assist in vaccine development. With the pressures of emerging viral strains constantly at our doorstep, the ability to model potential mutations and forecast their impact could play a crucial role in national health security. This innovative approach may thus serve as a blueprint for future interdisciplinary collaborations that fuse biology with computational sciences.

In conclusion, the comprehensive study undertaken by Sabir, Yessengaliyev, and Temirzhan marks a significant milestone in both the fields of virology and artificial intelligence. By pivoting towards a radial basis neural network, they have not only enhanced understanding of the hepatitis C virus but have also set a precedent for future research methodologies. Their work exemplifies the potential for technology to drive healthcare innovation, a necessity in an increasingly interconnected world facing multifaceted health challenges.

As this research awaits publication, the scientific community watches with anticipation, ready to engage with the insights it promises. The implications of such studies could pave the way for informed strategies, capable of tackling one of the most pressing health issues of our times, hepatitis C. The marriage of machine learning and virology stands as a beacon of hope for future healthcare advancements, embodying the spirit of innovation that could very well change the course of infectious disease management.

Subject of Research: Hepatitis C Virus Dynamics and Modeling

Article Title: Designing a novel radial basis neural structure for solving the dynamical hepatitis C virus model.

Article References:

Sabir, Z., Yessengaliyev, A., Temirzhan, A. et al. Designing a novel radial basis neural structure for solving the dynamical hepatitis C virus model.
Sci Rep (2025). https://doi.org/10.1038/s41598-025-29644-5

Image Credits: AI Generated

DOI: 10.1038/s41598-025-29644-5

Keywords: Hepatitis C virus, Radial Basis Function, Neural Networks, Viral Modeling, Artificial Intelligence, Infectious Disease Research.

Recent research conducted at the University of North Carolina at Charlotte has unveiled startling findings regarding the evolution of the H5N1 virus. Through innovative artificial intelligence methodologies and intricate physics-based modeling, the investigators meticulously examined thousands of viral proteins. The revelations indicate a worrying trend: the virus has developed new strategies that enable it to evade the defensive mechanisms produced by the human immune system. This adaptation not only compromises existing vaccines but raises serious concerns regarding the future trajectory of the virus.

The study draws upon data from over 1,800 H5N1 proteins, where the researchers utilized AlphaFold 3, an advanced artificial intelligence protein folding system, to predict the three-dimensional structures of these proteins. This computational approach allowed the scientists to understand how well these viral proteins interact with antibodies generated by the immune system. As they explored the binding affinity between these antibodies and the viral proteins, the researchers unearthed a troubling trend—over the years, this binding has significantly weakened.

Colby T. Ford, the lead researcher of the study and a computational biologist, expressed his concerns regarding the trajectory of H5N1, stating, “The virus has mutated away from the version we observed a decade ago.” He indicated that these changes have led to a distinct appearance at the molecular level, further illustrating the virus’s capacity for rapid evolution. These alterations have critical ramifications concerning how effective previously developed vaccines may be against current strains of H5N1.

Furthermore, the research team has been employing extensive datasets centered on H5N1 to delineate the various clades of the virus and their specific transmission dynamics. Understanding these pathways is crucial for mitigating the risks associated with potential outbreaks. For instance, the researchers recently implicated a particular clade in the H5N1-related death of an individual in Louisiana, highlighting the direct transmission link between birds and humans, without an intermediary host.

The ongoing analysis has substantial implications for public health and epidemiological strategies. The evolution of the H5N1 virus exemplifies the dynamic nature of pathogens and emphasizes the need to stay ahead of their adaptations. This necessitates a continual reevaluation of existing vaccines, which may no longer provide adequate protection against emerging strains due to their evolving characteristics.

Artificial intelligence is proving to be an invaluable asset in this field of study. The capabilities offered by AI and computational modeling are shedding light on the evolution of the H5N1 virus, ultimately aiding researchers in the identification of more effective antibodies and potential therapeutics. The research group has articulated a methodology through which molecular information from new and emerging strains can be utilized to formulate targeted therapies against the virus. Such advancements represent a promising avenue in the race to combat viral threats.

Another crucial aspect of the ongoing investigation is the potential development of novel therapeutics based on the currently circulating strains of H5N1. Ford emphasized the speed at which new treatments could be generated, stating, “The answer is yes, and we can do it fairly quickly with the AI pipeline we’ve built.” This emphasizes the transformative potential of integrating AI into virology and infectious disease research—a development that could dramatically alter the healthcare landscape.

The implications of this research extend beyond mere academic interest; they touch upon vital public health infrastructures globally. The ability to understand, track, and respond to viral mutations is essential for safeguarding populations against infectious diseases. The precarious balance that exists between humans and viruses such as H5N1 underscores the urgency for continued vigilance and innovation in the face of evolving pathogens.

In the grand tapestry of infectious disease research, the work carried out by Ford and his colleagues exemplifies a pivotal shift toward a more dynamic understanding of viral evolution. By harnessing the power of artificial intelligence and sophisticated modeling techniques, researchers are poised to unveil new strategies to combat incoming threats before they can spiral into pandemics.

The research findings were disseminated at the annual meeting of the American Society for Microbiology, a platform dedicated to advancing microbial sciences and offering critical insights into ongoing research efforts in the field. As scientists gather to share knowledge and strategies at such forums, the collective efforts may result in meaningful action towards mitigating the impacts of H5N1 and other infectious diseases on global health.

Understanding the complexities of H5N1’s evolution and its implications for human health is paramount to ensuring preparedness against future threats. As research in this arena continues to evolve and expand, one thing is clear: the time to act is now, with concerted efforts necessary to develop vaccines and therapeutics aligned with the virus’s adaptive mechanisms.

The ongoing investigation into H5N1 serves as a reminder that vigilance is essential in the era of emerging infectious diseases. With the advanced tools at researchers’ disposal, there remains hope for significant breakthroughs that can transform our response to these evolving threats and protect public health in an increasingly interconnected world.

As we deepen our understanding of H5N1 and its implications, it is crucial to foster collaboration across scientific disciplines to leverage diverse approaches toward tackling this complex issue. The convergence of artificial intelligence, biological research, and computational modeling offers an unprecedented opportunity to design more effective public health strategies, optimize vaccine development, and ultimately safeguard human health.

Subject of Research: Evolution of H5N1 Avian Influenza Virus
Article Title: Evolving Threats: Understanding the H5N1 Avian Influenza Virus
News Publication Date: [Insert Date]
Web References: [Insert URLs]
References: [Insert References]
Image Credits: [Insert Credits]

Keywords